AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS
Scope & Guideline
Unraveling the Mysteries of Amyloidosis
Introduction
Aims and Scopes
- Understanding Amyloid Diseases:
The journal emphasizes the study of various forms of amyloidosis, including AL, ATTR, and AA amyloidosis, exploring their molecular mechanisms, clinical presentations, and diagnostic challenges. - Innovative Diagnostic Techniques:
Methodologies such as mass spectrometry, imaging techniques, and biomarker discovery are frequently discussed, highlighting advancements in the detection and characterization of amyloid deposits. - Therapeutic Advances:
Research on treatment modalities, including pharmacological interventions like tafamidis and patisiran, is a core area, focusing on their efficacy, safety, and pharmacodynamics in different patient populations. - Multidisciplinary Approaches:
The journal promotes a multidisciplinary perspective, integrating insights from genetics, pathology, neurology, cardiology, and proteomics to provide a comprehensive understanding of amyloidosis. - Patient-Centric Research:
Studies that address patient experiences, outcomes, and the impact of amyloidosis on quality of life are essential, emphasizing the importance of patient-reported outcomes in clinical research.
Trending and Emerging
- Precision Medicine Approaches:
There is a significant trend towards personalized treatment strategies for amyloidosis patients, using genetic profiling and biomarkers to tailor therapies, particularly in hereditary forms of the disease. - Neurodegenerative Links:
Research increasingly explores the connections between amyloidosis and neurodegenerative diseases, particularly in understanding the role of amyloid deposits in conditions like Alzheimer's disease. - Longitudinal Studies and Real-World Evidence:
Emerging trends include a focus on longitudinal studies that assess treatment outcomes over time, providing valuable real-world evidence on the effectiveness of therapies. - Innovative Imaging Techniques:
Advancements in imaging modalities, such as PET and MRI, are becoming increasingly relevant for both diagnosis and monitoring of disease progression in amyloidosis. - Patient-Reported Outcomes and Quality of Life:
There is a growing emphasis on incorporating patient-reported outcomes into research, reflecting a broader recognition of the importance of quality of life for individuals living with amyloidosis.
Declining or Waning
- Historical Case Studies:
There has been a noticeable reduction in publications focusing on historical case reports of amyloidosis, suggesting a move towards more contemporary research and clinical trials. - Basic Science of Protein Folding:
Research primarily centered on fundamental aspects of protein folding without direct clinical or therapeutic implications seems to be waning, as the journal prioritizes studies with immediate clinical relevance. - Epidemiological Studies:
While still present, there is a decrease in the frequency of large-scale epidemiological studies on amyloidosis prevalence, indicating a possible shift towards more localized, specific studies or clinical trials. - Iatrogenic Amyloidosis Reports:
Reports concerning iatrogenic forms of amyloidosis, although significant, are appearing less frequently, which may reflect advancements in clinical practices that reduce such occurrences. - Animal Models in Amyloidosis Research:
Research utilizing animal models to study amyloidosis mechanisms is declining, possibly as the field shifts towards human-centric studies that yield more applicable results.
Similar Journals
Journal of Proteomics
Exploring the intricate world of proteins.Journal of Proteomics, published by Elsevier, is an esteemed peer-reviewed journal dedicated to advancing research in the field of proteomics, with broad implications for biochemistry and biophysics. Established in 2008, the journal has continuously evolved, embracing innovative methodologies and technologies that facilitate protein analysis from a variety of biological systems. With its current standing in the Q2 category for both biochemistry and biophysics as of 2023, it is recognized as a significant contributor to scientific literature. The journal publishes original research articles, reviews, and methodological advancements, providing invaluable insights for researchers, professionals, and students alike. Although it does not offer open access, the journal remains a crucial platform for disseminating knowledge that informs various applications, ranging from drug development to disease understanding. As it converges towards 2024, the Journal of Proteomics continues to solidify its role in shaping the future of proteomic research through rigorous scientific inquiry and innovation.
HemaSphere
Connecting researchers, clinicians, and students in hematology.HemaSphere, published by WILEY, stands at the forefront of hematology research, offering a vital platform for the dissemination of cutting-edge findings in the field. Since its inception in 2017 and official transition to Open Access in 2018, the journal has positioned itself as a leading conduit for high-impact research, maintaining a prestigious Q1 quartile ranking in the Hematology category as of 2023. Addressed in the United States at 111 River St, Hoboken, NJ, HemaSphere aims to foster a global dialogue among researchers, clinicians, and students by providing unrestricted access to high-quality content that encompasses clinical and experimental advancements. With an array of engaging articles, reviews, and commentaries, HemaSphere contributes significantly to the advancement of hematology, ensuring that critical knowledge is readily accessible to enhance patient care and innovative research. To explore the latest developments and breakthroughs in this dynamic field, we invite scholars, professionals, and students to engage with HemaSphere and elevate their understanding of hematologic science.
Clinical Proteomics
Connecting Research and Clinical Practice in ProteomicsClinical Proteomics is a leading open-access journal, published by BMC since 2011, that aims to advance the field of proteomics by providing a platform for the dissemination of original research, critical reviews, and technological advancements in the analysis of proteins and their roles in health and disease. With an ISSN of 1542-6416 and E-ISSN 1559-0275, this esteemed journal covers a broad scope, converging years of research from 2004 to 2024. As a distinguished publication, it holds a Q1 ranking in Clinical Biochemistry and Q2 in both Molecular Biology and Molecular Medicine, reflecting its significance in the scientific community. Clinical Proteomics' commitment to open access ensures that its content is readily available to researchers, professionals, and students worldwide, facilitating the exchange of knowledge and fostering collaborative efforts in proteomic studies. Situated in the United Kingdom, this journal plays a pivotal role in shaping the future of biomedical research, appealing to anyone keen on the integration of proteomics in clinical practice and molecular investigation.
MOLECULAR & CELLULAR PROTEOMICS
Transforming proteomics with high-impact research.MOLECULAR & CELLULAR PROTEOMICS, published by Elsevier, stands as a premier journal in the fields of Biochemistry, Analytical Chemistry, and Molecular Biology, with a distinguished Q1 ranking reflecting its high impact and contribution to the scientific community. Established in 2002, this journal has consistently provided a platform for the latest research in protein science, merging molecular biology with advanced analytical techniques. With impressive Scopus rankings—41st in Biochemistry and 16th in Analytical Chemistry—it caters to an audience of researchers, professionals, and students eager to explore cutting-edge developments in proteomics. Although currently not designated as open access, the journal aims to foster knowledge dissemination through accessible research content. As it continues to evolve until 2024, MOLECULAR & CELLULAR PROTEOMICS is essential for anyone passionately engaged in the ever-expanding field of proteomics.
Molecular Genetics & Genomic Medicine
Transforming discoveries into clinical applications.Molecular Genetics & Genomic Medicine, published by WILEY, is an esteemed and open-access journal that has been a prominent source of knowledge in the fields of genetics and molecular biology since its establishment in 2013. With an ISSN of 2324-9269, it aims to provide a platform for the dissemination of novel findings and innovative research that pushes the boundaries of genomics and its clinical applications. The journal holds a Q3 categorization in Genetics, Clinical Genetics, and Molecular Biology, reflecting its growing influence in these disciplines, as evidenced by its Scopus rankings. Researchers, professionals, and students alike will find valuable insights and advancements in genomic medicine, making this journal an essential resource for those dedicated to the understanding and application of genetic and molecular research in healthcare. Located at 111 River St, Hoboken, NJ, Molecular Genetics & Genomic Medicine continues to foster a global dialogue within the scientific community, ensuring accessible knowledge for all.
DYSPHAGIA
Uniting Experts to Tackle Dysphagia ChallengesDYSPHAGIA, published by Springer, is a premier journal dedicated to advancing the study of swallowing disorders, a critical area within the fields of Gastroenterology, Otorhinolaryngology, and Speech and Hearing. With an ISSN of 0179-051X and E-ISSN 1432-0460, this journal serves as a vital resource for researchers, clinicians, and students alike, providing cutting-edge research and reviews that inform clinical practice and enhance patient care. As a testament to its influence, DYSPHAGIA holds a Q2 ranking in Gastroenterology and Q1 rankings in both Otorhinolaryngology and Speech and Hearing for 2023. Its Scopus rankings further position it among the leading journals in its field, highlighting its importance and impact within the academic community. The journal publishes contributions that encompass a spectrum of topics related to swallowing, making it an essential platform for disseminating knowledge and fostering innovative solutions in the management of dysphagia. Operating from New York, NY, DYSPHAGIA invites contributions that align with its mission to advance the understanding and treatment of swallowing disorders through rigorous scientific inquiry and discourse.
Case Reports in Pediatrics
Championing Best Practices in Pediatric Healthcare.Case Reports in Pediatrics is a distinguished journal dedicated to the publication of high-quality case reports that illuminate specific pediatric clinical challenges and advancements. Published by HINDAWI LTD, this journal has established itself as an essential resource in the field of pediatric medicine, offering an open-access platform since 2011 to ensure that researchers, healthcare professionals, and students have unrestricted access to valuable insights. With an ISSN of 2090-6803 and an E-ISSN of 2090-6811, the journal aims to foster knowledge exchange and further the understanding of pediatric healthcare practices. This publication not only encourages the sharing of unique and rare case studies but also promotes best practices and innovative methodologies. In a rapidly evolving field, Case Reports in Pediatrics serves as a vital tool for professionals seeking to enhance patient care and inform clinical decision-making.
Proteomics Clinical Applications
Bridging Laboratory Discoveries and Patient CareProteomics Clinical Applications, published by Wiley-VCH Verlag GmbH, is a pivotal journal in the realm of Clinical Biochemistry, with an impressive track record since its inception in 2007, continuing its impactful contributions to 2024. With an ISSN of 1862-8346 and an E-ISSN of 1862-8354, this prestigious journal currently holds a commendable Q2 ranking in Clinical Biochemistry, situated at the 54th percentile among its peers within Scopus rankings. Dedicated to the advancement of proteomics and its applications in clinical settings, Proteomics Clinical Applications serves as a bastion for innovative research, fostering knowledge exchange among scientists, healthcare professionals, and students alike. Through its focus on novel methodologies and translational research, the journal aims to bridge the gap between laboratory findings and clinical practice, significantly impacting patient care and outcomes. Although not open access, its content is accessible through various academic databases, ensuring that vital research reaches its intended audience.
HPB
Elevating standards in liver and biliary disease research.HPB is a premier journal dedicated to advancing the fields of Gastroenterology and Hepatology, published by Elsevier Science Ltd. With an impressive impact factor reflective of its high-quality research output, HPB has earned its place as a Q1 journal in Gastroenterology and Q2 in Hepatology as of 2023. The journal, available in both print and electronic formats (ISSN: 1365-182X; E-ISSN: 1477-2574), serves as a vital platform for multidisciplinary research, encompassing clinical and experimental studies, aimed at improving patient care and outcomes related to liver and biliary diseases. Since its inception in 2000, HPB has published influential articles that have shaped practice and policy in the field. Located in the United Kingdom, at 125 London Wall, London EC2Y 5AS, the journal is poised to continue its mission of fostering innovation and collaboration among researchers, healthcare professionals, and academicians worldwide.
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
Empowering Scientific Dialogue in BiochemistryBIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS, published by Elsevier, is a prestigious academic journal that serves as a vital resource for researchers, professionals, and students in the fields of biochemistry, biophysics, and proteomics. With an ISSN of 1570-9639 and an E-ISSN of 1878-1454, this journal features high-impact research articles aimed at advancing our understanding of protein structure, function, and interactions, contributing significantly to both theoretical and applied sciences. Recognized for its quality, it proudly holds a Q1 ranking in Analytical Chemistry and Biophysics, and Q2 in Biochemistry for 2023, alongside notable Scopus rankings that reflect its influence in the realm of molecular biology. The journal's commitment to disseminating essential findings supports the ongoing evolution of proteomic sciences and encourages collaborative discourse among the global scientific community. For aspiring authors, the journal offers open access options, enabling broad visibility of their work. Join the conversation in this dynamic field and contribute to shaping the future of protein research!